Wealth Enhancement Advisory Services’s Krystal Biotech KRYS Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Buy	+651	New	+$195K	﹤0.01%	3428

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wealth Enhancement Advisory Services's KRYS Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Krystal Biotech (KRYS) in Q2 2026: 651 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #3428 among its holdings.

423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Wealth Enhancement Advisory Services held 651 shares of Krystal Biotech worth $238K as of Q2 2026.
Krystal Biotech was a new Wealth Enhancement Advisory Services position in Q2 2026.
Krystal Biotech made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3428 holding.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.